Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Zembrace Symtouch revenue
Tonix Pharmaceuticals Holding (TNXP) Zembrace Symtouch revenue by quarter
Tonix Pharmaceuticals Holding's Zembrace Symtouch revenue was $2.0M in Q2 2026 (second quarter 2026), -32% from Q1 2026. Over the last 6 quarters it ranged from $1.6M (Q2 2025) to $2.9M (Q1 2026).
| Quarter | Zembrace Symtouch revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.0M | -32% | +27% |
| Q1 2026 | $2.9M | +13% | +45% |
| Q3 2025 | $2.6M | +64% | — |
| Q2 2025 | $1.6M | -23% | — |
| Q1 2025 | $2.0M | -19% | — |
| Q4 2024 | $2.5M | — | — |
Q2 2026 at a glance
Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tonix Pharmaceuticals Holding's Zembrace Symtouch revenue?
Tonix Pharmaceuticals Holding's Zembrace Symtouch revenue was $2.0M in Q2 2026 (second quarter 2026), -32% from Q1 2026.
How has Tonix Pharmaceuticals Holding's Zembrace Symtouch revenue changed?
Over the last 6 quarters it ranged from $1.6M (Q2 2025) to $2.9M (Q1 2026).
Q2 2026 results → · How Tonix Pharmaceuticals Holding makes money →